A phase II study of the MDR inhibitor biricodar (INCEL, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples